C
Clara Oromendia
Researcher at Cornell University
Publications - 50
Citations - 1049
Clara Oromendia is an academic researcher from Cornell University. The author has contributed to research in topics: Prostate cancer & COPD. The author has an hindex of 14, co-authored 47 publications receiving 596 citations. Previous affiliations of Clara Oromendia include NewYork–Presbyterian Hospital.
Papers
More filters
Journal ArticleDOI
Clinical features of neuroendocrine prostate cancer
Vincenza Conteduca,Clara Oromendia,Kenneth Eng,Rohan Bareja,Michael Sigouros,Ana M. Molina,Bishoy Faltas,Andrea Sboner,Juan Miguel Mosquera,Olivier Elemento,David M. Nanus,Scott T. Tagawa,Karla V. Ballman,Himisha Beltran,Himisha Beltran +14 more
TL;DR: The clinical features of a cohort of patients with Neuroendocrine prostate cancer are described to inform future diagnostic strategies and could help guide when to perform a biopsy to look for NEPC histologic transformation.
Journal ArticleDOI
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers
Himisha Beltran,Himisha Beltran,Clara Oromendia,Daniel C. Danila,Daniel C. Danila,Bruce Montgomery,Christopher J. Hoimes,Russell Z. Szmulewitz,Ulka N. Vaishampayan,Andrew J. Armstrong,Mark N. Stein,Jacek Pinski,Juan Miguel Mosquera,Juan Miguel Mosquera,Verena Sailer,Rohan Bareja,Alessandro Romanel,Naveen Gumpeni,Andrea Sboner,Andrea Sboner,Etienne Dardenne,Loredana Puca,Loredana Puca,Davide Prandi,Mark A. Rubin,Mark A. Rubin,Howard I. Scher,Howard I. Scher,David S. Rickman,David S. Rickman,Francesca Demichelis,Francesca Demichelis,David M. Nanus,David M. Nanus,Karla V. Ballman,Scott T. Tagawa,Scott T. Tagawa +36 more
TL;DR: Although the study did not meet its primary endpoint, a subset of patients with advanced prostate cancer and molecular features supporting Aurora-A and N-myc activation achieved significant clinical benefit from single-agent alisertib.
Journal ArticleDOI
A phase I trial of low-dose inhaled carbon monoxide in sepsis-induced ARDS
Laura E. Fredenburgh,Mark A. Perrella,Diana Barragan-Bradford,Dean R. Hess,Elizabeth Peters,Karen E. Welty-Wolf,Bryan Kraft,R. Scott Harris,Rie Maurer,Kiichi Nakahira,Clara Oromendia,John D Davies,Angelica Higuera,Kristen T. Schiffer,Joshua A. Englert,Paul B. Dieffenbach,David A. Berlin,Susan Lagambina,Mark Bouthot,Andrew I. Sullivan,Paul Nuccio,Mamary Kone,Mona J. Malik,Maria Angelica Pabon Porras,Eli J. Finkelsztein,Tilo Winkler,Shelley Hurwitz,Charles N. Serhan,Claude A. Piantadosi,Rebecca M. Baron,B. Taylor Thompson,Augustine M.K. Choi +31 more
TL;DR: Precise administration of low-dose iCO is feasible, well-tolerated, and appears to be safe in patients with sepsis-induced ARDS and excellent agreement between predicted and observed COHb should ensure that COHB levels remain in the target range during future efficacy trials.
Journal ArticleDOI
Rapidly Improving ARDS in Therapeutic Randomized Controlled Trials
Edward J. Schenck,Clara Oromendia,Lisa K. Torres,David A. Berlin,Augustine M.K. Choi,Ilias I. Siempos,Ilias I. Siempos +6 more
TL;DR: Rapidly improving ARDS is an increasingly prevalent and distinct subphenotype, associated with better outcomes than ARDS > 1 day, and may negatively affect the prognostic enrichment and contribute to the failure of therapeutic trials.
Journal ArticleDOI
National trends in management of localized prostate cancer: A population based analysis 2004-2013.
TL;DR: This work sought to better understand how the changing landscape influenced treatment utilization in the United States as national screening guidelines have been updated and diagnostic practice patterns evolved.